Neocartilage and methods of use
AssigneeBarnes-Jewish Hospital
InventorHuston D. Adkisson
Life of this patent
Estimating the term…
Abstract
Disclosed are neocartilage compositions characterized by having multiple layers of cells, said cells being surrounded by a substantially continuous insoluble glycosaminoglycan and collagen-enriched hyaline extracellular matrix, and which neocartilage phospholipids are advantageously enriched in anti-inflammatory n-9 fatty acids, particularly 20:3 n-9 eicosatrienoic or Mead acid. Also disclosed are methods of growing neocartilage in substantially serum-free growth media and methods of producing a conditioned growth media containing compounds effective to enhance neocartilage formation. The neocartilage compositions are useful as implants and as replacement tissue for damaged or defective cartilage and as a model system for studying articular cartilage disease and response to natural and synthetic compounds.
Claims39
A pharmaceutical composition comprising an effective amount of cartilage substantially free of biglycan having multiple layers of cells randomly organized, rather than separated into distinct zones of chondrocyte maturation, surrounded by a substantially continuous insoluble glycosaminoglycan and collagen enriched hyaline extracellular matrix.
A pharmaceutical composition comprising an effective amount of cartilage containing membrane phospholipids depleted in linoleic acid.
A pharmaceutical composition comprising an effective amount of cartilage containing membrane phospholipids depleted in arachidonic acid.
A pharmaceutical composition comprising an effective amount of cartilage containing a matrix substantially free of biglycan.
A pharmaceutical composition comprising an effective amount of cartilage characterized as follows:
- (a) containing membrane phopholipids enriched in Mead acid and depleted in linoleic and arachidonic acid;
- (b) being enriched in high molecular weight aggrecan;
- (c) being substantially free of endothelial, bone and synovial cells;
- (d) being substantially free of biglycan.
A pharmaceutical composition comprising an effective amount of cartilage containing membrane phospholipids and having multiple layers of cells randomly organized, rather than separated into distinct zones of chondrocyte maturation, wherein:
- (a) said membrane phospholipids are enriched in Mead acid and depleted in linoleic and arachidonic acid;
- (b) said cartilage is enriched in high molecular weight aggrecan;
- (c) said cartilage is substantially free of endothelial, bone, and synovial cells;
- and
- (d) said cartilage is substantially free of biglycan.
A pharmaceutical composition comprising an effective amount of cartilage enriched in Mead acid and substantially free of endothelial, bone, and synovial cells.
A pharmaceutical composition comprising an effective amount of cartilage enriched in Mead acid and depleted in linoleic and arachadonic acid.
A pharmaceutical composition comprising an effective amount of cartilage enriched in high molecular weight aggrecan and in Mead acid.
A pharmaceutical composition comprising an effective amount of cartilage substantially free of endothelial, bone and synovial cells and type I, III, and X collagen.
A pharmaceutical composition comprising an effective amount of cartilage enriched in high molecular weight aggrecan and substantially free of endothelial, bone, and synovial cells.
Dependencies are inferred from the claim text.